Documentation of published clinical trials and ... - Institut Hiscia

Survival Urogenital Cancer Ovary 5.1.2.1
Hassauer W., Gutsch J., Burkhardt R. (1979) Welche Erfolgsaussichten bietet die Iscador-
Therapie beim fortgeschrittenen Ovarialkarzinom? [How much success can an iscador therapy
by advanced ovarial cancer offer?] Onkologie 2 (1), 28–36.
Study design
Design Retrospective study with historical control.
Patients 25 patients with primary ovarian neoplasms, operated; 22 control patients.
After accounting for comparability of the two groups, 12 Iscador patients
remained (7 with stage III disease, 5 with stage IV disease) and 18 control
patients (13 with stage III disease, 5 with stage IV disease).
Treatment Iscador s.c. in different doses.
Length of study 1969–1976.
Measurement Survival.
Most important results
The 5-year survival rate was 100% in patients with disease at stages I and II, 28% with patients at
stage II and 0% in patients at stage IV. In a historical comparison with a collective of patients
with ovarian cancer, treated with the cytostatic Cytoval, the Iscador group (stage III and IV)
achieved a longer mean survival of 16.2 months compared with 5.2 months in the Cytoval
group, despite disadvantageous prognostic conditions. The patients with stage III disease lived
4.2 times longer under treatment with Iscador, and in stage IV 1.6 times longer. The difference
was statistically significant (p < 0.018).
7 patients in the Cytoval group suffered severe side-effects from the therapy. No such problems
were reported in the Iscador group, the reverse was the case, well-being improved and
requirements for analgesics decreased.
Fig. 1: Course of survival of patients with ovarian cancer under therapy with
Cytoval and Iscador respectively (graph according to Hassauer et al. 1979).
© Verein für Krebsforschung, CH-4144 Arlesheim